2024-12-01 - Analysis Report
## Johnson & Johnson (JNJ) Stock Review

This report analyzes Johnson & Johnson (JNJ), a leading healthcare company producing pharmaceuticals, medical devices, and consumer health products.

**1. Performance vs. S&P 500 (VOO):**

JNJ's cumulative return (37.02%) significantly underperformed the S&P 500 (VOO) with a cumulative return of 130.06%.  The difference is -93.0%, placing it at the 1.2 percentile of its historical range of relative performance compared to the S&P 500.  The provided alpha values consistently show near-zero performance relative to the market benchmark, suggesting the stock's returns closely track the overall market performance (beta is not shown to be significantly different from 1, and CAGR fluctuates).  This means JNJ's performance has lagged the broader market substantially.

**2. Recent Price Movement:**

* **Last Price:** $155.01
* **5-Day Moving Average:** $154.68
* **20-Day Moving Average:** $154.24
* **60-Day Moving Average:** $159.19

The price is currently below all three moving averages, suggesting a possible downtrend. The recent closing price ($155.4) is above the 5-day and 20-day averages but below the 60-day average.  There is no indication of a significant sudden price jump or drop.

**3. Technical Indicators & Expected Return:**

* **RSI:** 52.76 (Slightly above neutral; not overbought or oversold)
* **PPO:** 0.31 (Positive, suggesting bullish momentum, but low magnitude)
* **20-Day Relative Strength Change:**  `nan` (Missing data prevents analysis of short-term relative strength trend)
* **Expected Return:** 0.0% (This indicates no expected outperformance relative to the S&P 500 for a long-term (2+ years) investment, based on the provided data)


**4. Recent Earnings Analysis:**

The provided earnings data shows some volatility in both EPS and revenue.

* **EPS:** Fluctuated significantly across the quarters,  peaking at $10.32 in Q4 2023 and then substantially dropping in subsequent quarters.  This volatility warrants further investigation.

* **Revenue:**  Revenue is relatively stable and around $21-22 billion across the reported quarters. A minor decrease is visible between Q1 2024 and Q4 2023, followed by slight increases in Q2 and Q3 of 2024.  Without further context, this doesn't provide a clear trend.

* **Comparison:**  There is no benchmark to compare earnings to; therefore,  no "beats" or "misses" can be determined.


**5. Financial Information:**

* **Revenue and Profitability:** Revenue has remained relatively stable, while profit margins have fluctuated slightly, remaining generally high (around 69%).
* **Capital and Profitability:**  Equity and ROE show some fluctuations. The exceptionally high ROE of 36.54% in Q3 2023 stands out and requires further investigation to understand the underlying factors.

**6. News and Recent Issues:**

No recent news (within the last two days) or analyst opinions were provided.  The lack of market outlook information limits a complete analysis of current investor sentiment.

**7. Overall Analysis:**

JNJ has significantly underperformed the S&P 500 over the provided period.  While its financial statements reveal relatively stable revenue and high profit margins, the EPS volatility and fluctuations in ROE raise concerns. The technical indicators provide a mixed signal, with RSI suggesting neutral conditions and PPO hinting at weak positive momentum. The missing relative strength data and lack of recent news prevent a complete picture. The expected return of 0% relative to the S&P 500 suggests no significant outperformance is anticipated for long-term buy-and-hold strategies.  Further investigation into the Q3 2023 exceptionally high ROE and the significant drop in EPS are necessary.

**8. Recommendations:**

Given the underperformance relative to the market and the volatility in earnings, a cautious approach is warranted.  More comprehensive data, including analyst ratings, future earnings expectations, and an explanation for the unusual spike in ROE and subsequent drop in EPS, are crucial for a complete evaluation.  Currently, without additional information, it's difficult to make a strong buy or sell recommendation.
